Publications by authors named "L Leichman"
Background: 5-Fluorouracil (5-FU) is a major component of gastrointestinal cancer treatments. In multidrug regimens such as FOLFOX, FOLFIRI, and FOLFIRINOX, 5-FU is commonly administered as a bolus followed by an infusion. However, the pharmacologic rationale for incorporating the 5-FU bolus in these regimens is unclear, and there are other effective regimens for gastrointestinal cancers that do not include the bolus.
View Article and Find Full Text PDFArticle Synopsis
- Trastuzumab is a monoclonal antibody targeting HER2, and the NRG Oncology/RTOG-1010 trial aimed to determine its effectiveness in improving disease-free survival for patients with untreated HER2-overexpressing oesophageal adenocarcinoma when combined with standard treatments.
- The trial was a phase 3, open-label study, recruiting 203 eligible adult patients from various institutions in the USA who had newly diagnosed oesophageal adenocarcinoma, stratified by their adenopathy status and randomly assigned to receive chemoradiotherapy with or without trastuzumab.
- The primary goal of the study was to measure disease-free survival, defined as the time from randomization to death or recurrence of cancer, and the
An oncologist describes the loss of his wife, also an oncologist, to brain cancer and his subsequent life‐changing decisions.
View Article and Find Full Text PDFMolecular profiling of circulating tumor DNA (ctDNA) is a promising noninvasive tool. Here, next-generation sequencing (NGS) of blood-derived ctDNA was performed in patients with advanced colorectal cancer. We investigated ctDNA-derived genomic alterations, including potential actionability, concordance with tissue NGS, and serial dynamics in 78 patients with colorectal cancer using a clinical-grade NGS assay that detects single nucleotide variants (54-73 genes) and selected copy-number variants, fusions, and indels.
View Article and Find Full Text PDFPhase II Study of Preoperative Chemoradiotherapy with Oxaliplatin, Infusional 5-Fluorouracil, and Cetuximab Followed by Postoperative Docetaxel and Cetuximab in Patients with Adenocarcinoma of the Esophagus: A Trial of the ECOG-ACRIN Cancer Research Group (E2205).
Oncologist
January 2020
Background: A standard approach to treating resectable esophageal adenocarcinoma is chemoradiotherapy (CRT) followed by surgery; however, recurrence is common. To improve this, we designed a single-arm, phase II trial that added an epidermal growth factor receptor (EGFR) inhibitor, cetuximab (C), to CRT, with the hypothesis that EGFR inhibition would improve pathologic complete response (pCR) rate.
Materials And Methods: We aimed to increase the pCR rate from 25% to 45%.